S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

Statera Biopharma (STAB) Competitors

$0.0006
0.00 (0.00%)
(As of 03/1/2024 ET)

STAB vs. NOVN, NOVNQ, SCPS, CALA, HGEN, PKBO, VRAYQ, AHPI, IGNY, and HTGMQ

Should you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Novan (NOVN), NVN Liquidation (NOVNQ), Scopus BioPharma (SCPS), Calithera Biosciences (CALA), Humanigen (HGEN), Peak Bio (PKBO), ViewRay (VRAYQ), Allied Healthcare Products (AHPI), Ignyte Acquisition (IGNY), and HTG Molecular Diagnostics (HTGMQ). These companies are all part of the "medical" sector.

Statera Biopharma vs.

Statera Biopharma (NASDAQ:STAB) and Novan (NASDAQ:NOVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Statera Biopharma has a net margin of 0.00% compared to Novan's net margin of -128.61%. Statera Biopharma's return on equity of 0.00% beat Novan's return on equity.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Novan -128.61%-700.28%-39.58%

Novan has a consensus price target of $8.00, suggesting a potential upside of 999,900.00%. Given Novan's higher probable upside, analysts plainly believe Novan is more favorable than Statera Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Statera Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Novan
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

14.5% of Novan shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 1.3% of Novan shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novan has higher revenue and earnings than Statera Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera Biopharma$1.49M0.02-$101.85MN/AN/A
Novan$24.71M0.00-$31.31M-$1.320.00

In the previous week, Novan had 1 more articles in the media than Statera Biopharma. MarketBeat recorded 2 mentions for Novan and 1 mentions for Statera Biopharma. Statera Biopharma's average media sentiment score of 0.00 equaled Novan'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Statera Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novan
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novan received 239 more outperform votes than Statera Biopharma when rated by MarketBeat users.

CompanyUnderperformOutperform
Statera BiopharmaN/AN/A
NovanOutperform Votes
239
57.31%
Underperform Votes
178
42.69%

Statera Biopharma has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Novan has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

Summary

Novan beats Statera Biopharma on 7 of the 13 factors compared between the two stocks.


Get Statera Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

STAB vs. The Competition

MetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$33,000.00$7.30B$5.21B$7.62B
Dividend YieldN/A2.84%2.82%3.87%
P/E RatioN/A19.21257.1618.81
Price / Sales0.02452.263,095.74110.41
Price / CashN/A19.1499.8655.35
Price / BookN/A4.704.534.54
Net Income-$101.85M$162.03M$114.95M$211.55M
7 Day PerformanceN/A7.67%5.71%3.36%
1 Month PerformanceN/A15.58%11.26%6.68%
1 Year PerformanceN/A9.19%13.49%8.85%

Statera Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NOVN
Novan
0.8788 of 5 stars
$0.00
flat
$8.00
+888,788.9%
-99.9%$25,000.00$24.71M0.0090Analyst Report
NOVNQ
NVN Liquidation
0 of 5 stars
$0.00
flat
N/AN/A$25,000.00$23.68M0.0090News Coverage
SCPS
Scopus BioPharma
0 of 5 stars
$0.00
flat
N/A-97.0%$84,000.00N/A0.0013
CALA
Calithera Biosciences
0 of 5 stars
$0.03
flat
N/A-60.0%$122,000.00$9.75M0.008
HGEN
Humanigen
0 of 5 stars
N/A$0.50
+∞
N/A$24,000.00$1.70M0.006News Coverage
PKBO
Peak Bio
0 of 5 stars
$0.00
flat
N/A-99.8%$45,000.00$610,000.000.0021
VRAYQ
ViewRay
0 of 5 stars
N/AN/AN/A$20,000.00$102.21M0.00295
AHPI
Allied Healthcare Products
0 of 5 stars
N/AN/AN/A$16,000.00$27.05M0.00189
IGNY
Ignyte Acquisition
0 of 5 stars
$0.00
flat
N/A-99.8%$15,000.00N/A0.00N/A
HTGMQ
HTG Molecular Diagnostics
0 of 5 stars
$0.01
flat
N/AN/A$11,000.00$6.37M0.0053

Related Companies and Tools

This page (NASDAQ:STAB) was last updated on 3/3/2024 by MarketBeat.com Staff